115 results
8-K
EX-99.1
BLPH
Bellerophon Therapeutics, Inc.
5 Jun 23
Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
8:08am
biotherapeutics company focused on developing innovative therapies that address significant unmet medical needs in the treatment of cardiopulmonary diseases
424B5
49qimf9ce
31 May 23
Prospectus supplement for primary offering
4:40pm
8-K
EX-99.1
afsmc
15 May 23
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
4:54pm
8-K
258xlpq 2qlj5oun8jyx
11 May 23
Departure of Directors or Certain Officers
5:06pm
8-K
EX-99.1
d5jfpyqu
11 May 23
Pivotal top-line data readout expected in mid-2023
8:30am
8-K
EX-99.1
4qda4b1grj3ti y3
31 Mar 23
Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results
8:29am
8-K
EX-99.1
zy7wi5tx1azb0
14 Nov 22
Bellerophon Provides Clinical Program Update and Reports Third Quarter 2022 Financial Results
9:12am
8-K
EX-99.1
n62d34q3ytmoifu
27 Sep 22
Bellerophon Announces FDA Acceptance of Change to Ongoing Phase 3 REBUILD Study of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease
8:28am
8-K
EX-99.1
9csds3ej8s o6
15 Aug 22
Bellerophon Provides Clinical Program Update and Reports Second Quarter 2022 Financial Results
8:41am
8-K
EX-99.1
j8wpphb
11 May 22
Bellerophon Provides Clinical Program Update and Reports First Quarter 2022 Financial Results
8:34am